Arcutis: Every Beat Gets Absorbed By A Shrinking Multiple (Rating Downgrade)
(NASDAQ:ARQT) Seeking Alpha - Arcutis Biotherapeutics is downgraded from Buy to a cautious Hold as valuation now reflects current fundamentals and future risk-reward is balanced. - Management raised 2026 revenue guidance to $525–$540 million, but foam/cream mix improvement is modest, and new-patient…